TRVI
Trevi Therapeutics Inc

1,782
Loading...
Loading...
News
all
press releases
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
Zacks·4mo ago
News Placeholder
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics Completes Enrollment for Phase 2b CORAL...
PR Newswire·7mo ago
News Placeholder
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
Trevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire NEW HAVEN, Conn., Jan. 30, 2025 NEW...
PR Newswire·8mo ago
News Placeholder
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics Announces Company...
PR Newswire·8mo ago
News Placeholder
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering PR Newswire NEW HAVEN, Conn., Dec. 16, 2024 NEW...
PR Newswire·9mo ago
News Placeholder
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%
An independent statistician confirmed the sample size following a re-estimation analysis, ensuring that the trial’s design remains statistically robust.
Stocktwits·9mo ago
News Placeholder
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients...
PR Newswire·9mo ago
News Placeholder
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of...
PR Newswire·10mo ago
News Placeholder
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference PR Newswire NEW HAVEN, Conn...
PR Newswire·10mo ago

Latest TRVI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.